A population model of epirubicin pharmacokinetics and application to dosage guidelines

Cancer Chemotherapy and Pharmacology

Volumn 52, Issue 1, 2003, Pages 34-40

  Ralph, Lorraine D ^a,d   Thomson, Alison H ^a,b   Dobbs, Nicola A ^c   Twelves, Chris ^c  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b WESTERN INFIRMARY   (United Kingdom)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^d IQVIA   (United States)

Author keywords

Epirubicin; Liver dysfunction; Population pharmacokinetics

Indexed keywords

ANTHRACYCLINE; ASPARTATE AMINOTRANSFERASE; EPIRUBICIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BILIRUBIN BLOOD LEVEL; BREAST CANCER; CLINICAL TRIAL; DRUG CLEARANCE; DRUG DOSE REGIMEN; FEMALE; HUMAN; LIVER METASTASIS; MAJOR CLINICAL STUDY; POPULATION MODEL; PRACTICE GUIDELINE; PRIORITY JOURNAL;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; AREA UNDER CURVE; ASPARTATE AMINOTRANSFERASES; BREAST NEOPLASMS; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIRUBICIN; FEMALE; HUMANS; LIVER NEOPLASMS; METABOLIC CLEARANCE RATE; MIDDLE AGED; POPULATION SURVEILLANCE;

EID: 0041669246     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-003-0608-x     Document Type: Article

References (22)

1. Beal SL, Sheiner LB (1992) NONMEM (user's guide), parts 1-VII. Technical Report, University of California, San Francisco
2. Camaggi CM, Strocchi E, Tamassia V, Martoni A, Giovannini M, Iafelice G, Canova N, Marraro D, Martini A, Pannuti F (1982) Pharmacokinetic studies of 4′-epi-doxorubicin in cancer patients with normal and impaired renal function and with liver metastases. Cancer Treat Rep 66:1819
3. Cook RD (1977) Detection of influential observation in linear regression. Technometrics 19:15
4. Coukell AJ, Faulds D (1997) Epirubicin. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of breast cancer. Drugs 53:453
5. Dobbs NA, Twelves CJ (1998) What is the effect of adjusting epirubicin doses for body surface area? Br J Cancer 78:662
6. Dobbs NA, Twelves CJ (1991) Measurement of epidoxorubicin and its metabolites by high-performance liquid chromatography using an advanced automated sample processor. J Chromatogr 572:211
7. Dobbs NA, Twelves CJ, Gregory W, Cruickshanka C, Richards MA, Rubens RD (2003) Epirubicin in patients with liver dysfunction: development and evaluation of a novel dose modification scheme. Eur J Cancer 39:580-586
8. Epirubicin Product Label, UK (2003) http://emc.vhn.net
9. Epirubicin Product Label, USA (2003) www.fda.gov/cder/foi/label/1999/507781b1.pdf
10. Favier M, deCazanove F, Saint Martin F, Bressolle F (1994) Preventing medication errors in antineoplastic therapy. Am J Hosp Pharm 51:832
11. Grochow LB, Baraldi C, Noe D (1990) Is dose normalization to weight or body surface area useful in adults? J Natl Cancer Inst 82:323
12. Gurney HP, Ackland S, Gebski V, Farrell G (1998) Factors affecting epirubicin pharmacokinetics and toxicity: evidence against using body-surface area for dose calculation. J Clin Oncol 16:2299
13. Jakobsen P, Basholt L, Dalmark M, Pfeiffer P, Petersen D, Gjedde SB, Sandberg E, Rose C, Nielsen OS, Mouridsen HT (1991) A randomised study of epirubicin at four different dose levels in advanced breast cancer. Feasibility of myelotoxicity prediction through single blood-sample measurement. Cancer Chemother Pharmacol 28:465
14. Jonsson EN, Karlsson MO (1999) Xpose - an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 58:51
15. Plosker GL, Faulds D (1993) Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy. Drugs 45:788
16. Robert J (1994) Clinical pharmacokinetics of epirubicin. Clin Pharmacokinet 26:428
17. Robert J (1993) Epirubicin. Clinical pharmacology and dose-effect relationship. Drugs 45:20
18. Rodvold KA, Rushing DA, Tewksbury DA (1988) Doxorubicin clearance in the obese. J Clin Oncol 6:1321
19. Sheiner LB, Beal SL (1980) Evaluation of methods for estimating population pharmacokinetic parameters I. Michaelis-Menten model: routine clinical pharmacokinetic data. J Pharmacokinet Biopharm 8:553
20. Sheiner LB, Beal SL (1981) Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 9:503
21. Twelves CJ, Dobbs NA, Michael Y, Summers LA, Gregory W, Harper PG, Rubens RD, Richards MA (1992) Clinical pharmacokinetics of epirubicin: the importance of liver biochemistry tests. Br J Cancer 66:765
22. Weenan H, Lankelma H, Penders PGM, McVie JG, Ten Bokkel Huinink WW, de Planque MM, Pinedo HM (1983) Pharmacokinetics of 4′-epi-doxorubicin in man. Invest New Drugs 1:59